Allergan, Inc. v. Revance Therapeutics, Inc.

CourtDistrict Court, M.D. Tennessee
DecidedMarch 17, 2025
Docket3:23-cv-00431
StatusUnknown

This text of Allergan, Inc. v. Revance Therapeutics, Inc. (Allergan, Inc. v. Revance Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Allergan, Inc. v. Revance Therapeutics, Inc., (M.D. Tenn. 2025).

Opinion

UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

ALLERGAN, INC., ALLERGAN ) PHARMACEUTICALS IRELAND, ) UNLIMITED COMPANY, ALLERGAN ) USA, INC., AND ALLERGAN SALES, LLC ) Civil Action No. 3:23-cv-00431 Plaintiffs, ) Judge Richardson/Frensley ) v. ) ) REVANCE THERAPEUTICS, INC. ) Defendant. )

ORDER OF THE SPECIAL MASTER RESOLVING PLAINTIFFS’ MOTION TO COMPEL SEARCHING OF DEVICES USED UNDER REVANCE’S BYOD POLICIES

This case comes before the Special Master on Plaintiffs’ Motion to Compel Searching of Devices Used Under Revance’s BYOD Policies (ECF 255) (the “Motion”). Upon consideration of the sealed brief in support (ECF 240),1 the response in opposition (ECF 268), the relevant sealed position statement of the parties (ECF 238), and the relevant exhibits the parties submitted (ECF 241; ECF 242; ECF 255-2; ECF 255-5; ECF 255-6; ECF 255-7; ECF 255-8; ECF 269-1; ECF 269-2), the Special Master DENIES the Motion. I. General Background This is a trade secrets misappropriation case. Two classes of cosmetic products are at issue: (1) biologic therapeutics employing botulinum neurotoxin (“BoNT”) and (2) dermal fillers. Plaintiffs (various entities doing business under the “Allergan” trade name)2 allege that Defendant Revance Therapeutics, Inc.3 misappropriated trade secrets related to Plaintiffs’ popular products

1 Because Revance is not seeking to seal Exhibits A or B to the Declaration of Jennifer Baldocchi (ECF 255-2 ¶¶ 2–3; ECF 241; ECF 242), see ECF 270 at 1, the Special Master cites to and discusses herein portions of the sealed brief in support that reference these exhibits. 2 This Order refers to Plaintiffs as “Plaintiffs” and “Allergan” interchangeably. 3 This Order refers to Defendant as “Defendant” and “Revance” interchangeably. Botox (a BoNT therapeutic) and Juvéderm (a dermal filler). See, e.g., Compl. (ECF 1) ¶ 1. Defendant allegedly accomplished this misappropriation by hiring Allergan employees and, presumably, encouraging them to take Plaintiffs’ trade secrets with them. See, e.g., id. ¶¶ 7–8, 10, 75, 87. Discovery in this case has been lengthy. The parties have been conducting discovery pursuant to an agreed Joint Discovery Plan (ECF 90; ECF 223), which provides a framework for, among other things, the production of electronically stored information (“ESI”).4 Despite the

parties’ agreement on that basic framework, various discovery disputes have ensued. On July 14, 2023, Allergan served its First Set of Requests for Production on Revance. (ECF 255-2 ¶ 11; ECF 255-8). Among other requests, Allergan requested that Revance produce documents responsive to the following categories: • RFP No. 14: All communications between any current or former Allergan employee, including, but not limited to, the individuals listed in [the list of employees who left Allergan for Revance], and Revance referencing Allergan. • RFP No. 18: All Allergan documents that Revance has in its possession, custody, or control. • RFP No. 19: All documents that Revance has in its possession, custody, or control that contain Allergan information. • RFP No. 87: Documents sufficient to identify each customer of DaxibotulinumtoxinA for Injection in the United States. (ECF 240 at 2; ECF 255-8 at 3–4). On November 15, 2024, the parties jointly moved the Court to “appoint a discovery special master to resolve discovery disputes,” “[g]iven the number of discovery disputes currently pending

4 The parties Joint Discovery Plan does not displace the background ESI principles of the Middle District’s Administrative Order 174-1. See ECF 90 ¶ 8(a) (“This ESI Protocol [within the Joint Discovery Plan] applies to the ESI provisions of Federal Rules of Civil Procedure 26, 33, 34, and 37, and Administrative Order 174-1 of the U.S.D.C. Middle District of Tennessee.”); (ECF 223 ¶ 8(a) (same)). before the Court and the number of disputes expected to be raised in the future based on the parties’ discussions.” (ECF 271 ¶ 6). The Court granted that request on November 18, 2024, stating that it would appoint a special master to rule on “all discovery matters currently pending before the Court, and all future discovery disputes.” (ECF 275 ¶ 1). On December 11, 2024, the Court appointed the undersigned as Special Master. (ECF 292). II. Issues Raised by the Motion The Motion concerns Allergan’s request to compel Revance to search the personal devices of four individuals for documents responsive to Allergan’s discovery requests.5 These four

individuals are Alexis Jammo, Domenico Vitarella, Todd Gross, and Roy Yoshimitsu, all of whom previously worked for Allergan and then worked for Revance. Each of these individuals used his or her personal devices while working for Revance pursuant to Revance’s Mobile Device Policy, or “Bring Your Own Device” policy (“BYOD Policy”). (ECF 255-5 at 2; ECF 255-6 at 2). Allergan contends that the BYOD Policy (ECF 269-2) and the Revance Employee Handbook (“Handbook”) (ECF 269-1), when read in tandem, support compelling Revance to search its employees’ personal devices. Revance disagrees that it has possession, custody, or control over its employees’ personal devices used pursuant to the BYOD Policy and raises privacy concerns.6

5 Allergan contends that RFPs 14, 18, 19 and 87 are “just a few examples” of requests for which responsive documents “will be found on the devices of the former Allergan employees at issue here.” (ECF 240 at 2). 6 Allergan generally asserted that discovery of Revance employees’ personal devices is proportional to the needs of the case (ECF 240 at 1) and Revance did not argue otherwise, (ECF 268, passim), so the Special Master assumes for purposes of this Order that the discovery falls within Rule 26’s proportionality standard. Moreover, the parties’ briefing indicates that Allergan chose not to issue Rule 45 subpoenas directly to the subject employees and this Order therefore addresses only whether Revance has sufficient Rule 34(a) control over its employees’ personal devices to require it to obtain and produce data from those personal devices. See Halabu Holdings, Inc. v. Old Nat’l Bancorp, No 20-10427, 2020 WL 12676263, at *3 (E.D. Mich. June 9, 2020) (noting that, “[o]f course, personal devices owned by non-defendant employees are not immunized from discovery,” that, “[l]ike most other sources of information, they can be reached by way of a A. Relevant Excerpts from the Handbook

The Revance Handbook “is intended to give [employees] the framework and guidelines that should assist [them] in the performance of [their] job and the accomplishment of [their] goals.” (ECF 269-1 at 2). Under the heading “COMPANY PROPERTY,” the Handbook contains a “Search Policy” section. Id. at 48–49. The “Search Policy” section describes “Company property” and Revance’s inspection rights associated with Company property. Id. According to this policy, Furniture, desks, computers, cell phones, data processing equipment/software, vehicles, and other company-owned items are Company property and must be maintained according to Company rules and regulations . . . . The Company reserves the right to inspect all Company property including computer or phone data or messages to ensure compliance with its rules and regulations, without notice to the employee and at any time, not necessarily in the employee’s presence. There is no expectation of privacy in the possession or use of any Company property.

Id. at 48. The Handbook also contains an “Electronic and Social Media” section. Id. at 49–50. The section starts with several definitions, including, “Computers” are defined as . . . handheld devices (including but not limited to smart phones, and other electronic tablets and cell phones) . . . and other Company-owned items. . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Bankers Trust Company
61 F.3d 465 (Sixth Circuit, 1995)
DeGeer v. Gillis
755 F. Supp. 2d 909 (N.D. Illinois, 2010)
Flagg ex rel. Bond v. City of Detroit
252 F.R.D. 346 (E.D. Michigan, 2008)
Gross v. Lunduski
304 F.R.D. 136 (W.D. New York, 2014)
Weck v. Cross
88 F.R.D. 325 (N.D. Illinois, 1980)
Resolution Trust Corp. v. Deloitte & Touche
145 F.R.D. 108 (D. Colorado, 1992)
Bank of New York v. Meridien BIAO Bank Tanzania Ltd.
171 F.R.D. 135 (S.D. New York, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Allergan, Inc. v. Revance Therapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/allergan-inc-v-revance-therapeutics-inc-tnmd-2025.